Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Leonid Cherkassky, … , Michel Sadelain, Prasad S. Adusumilli


Following immune attack, solid tumors upregulate coinhibitory ligands that bind to inhibitory receptors on T cells. This adaptive resistance compromises the efficacy of chimeric antigen receptor (CAR) T cell therapies, which redirect T cells to solid tumors. Here, we investigated whether programmed death-1–mediated (PD-1–mediated) T cell exhaustion affects mesothelin-targeted CAR T cells and explored cell-intrinsic strategies to overcome inhibition of CAR T cells. Using an orthotopic mouse model of pleural mesothelioma, we determined that relatively high doses of both CD28- and 4-1BB–based second-generation CAR T cells achieved tumor eradication. CAR-mediated CD28 and 4-1BB costimulation resulted in similar levels of T cell persistence in animals treated with low T cell doses; however, PD-1 upregulation within the tumor microenvironment inhibited T cell function. At lower doses, 4-1BB CAR T cells retained their cytotoxic and cytokine secretion functions longer than CD28 CAR T cells. The prolonged function of 4-1BB CAR T cells correlated with improved survival. PD-1/PD-1 ligand [PD-L1] pathway interference, through PD-1 antibody checkpoint blockade, cell-intrinsic PD-1 shRNA blockade, or a PD-1 dominant negative receptor, restored the effector function of CD28 CAR T cells. These findings provide mechanistic insights into human CAR T cell exhaustion in solid tumors and suggest that PD-1/PD-L1 blockade may be an effective strategy for improving the potency of CAR T cell therapies.

Find the latest version:
http://jci.me/83092-pdf
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Leonid Cherkassky,1,2 Aurore Morello,1,2 Jonathan Villena-Vargas,1,2 Yang Feng,3 Dimitar S. Dimitrov,2 David R. Jones,2 Michel Sadelain,1 and Prasad S. Adusumilli1,2

Center for Cell Engineering and Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3Protein Interactions Section, Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland, USA.

Following immune attack, solid tumors upregulate coinhibitory ligands that bind to inhibitory receptors on T cells. This adaptive resistance compromises the efficacy of chimeric antigen receptor (CAR) T cell therapies, which redirect T cells to solid tumors. Here, we investigated whether programmed death-1–mediated (PD-1–mediated) T cell exhaustion affects mesothelin-targeted CAR T cells and explored cell-intrinsic strategies to overcome inhibition of CAR T cells. Using an orthotopic mouse model of pleural mesothelioma, we determined that relatively high doses of both CD28- and 4-1BB–based second-generation CAR T cells achieved tumor eradication. CAR-mediated CD28 and 4-1BB costimulation resulted in similar levels of T cell persistence in animals treated with low T cell doses; however, PD-1 upregulation within the tumor microenvironment inhibited T cell function. At lower doses, 4-1BB CAR T cells retained their cytotoxic and cytokine secretion functions longer than CD28 CAR T cells. The prolonged function of 4-1BB CAR T cells correlated with improved survival. PD-1/PD-1 ligand [PD-L1] pathway interference, through PD-1 antibody checkpoint blockade, cell-intrinsic PD-1 shRNA blockade, or a PD-1 dominant negative receptor, restored the effector function of CD28 CAR T cells. These findings provide mechanistic insights into human CAR T cell exhaustion in solid tumors and suggest that PD-1/PD-L1 blockade may be an effective strategy for improving the potency of CAR T cell therapies.

Introduction

Chimeric antigen receptors (CARs) are synthetic receptors that retarget T cells to tumor surface antigens (1, 2). First-generation receptors typically link an antibody-derived tumor-binding element to either CD3ζ or Fc receptor signaling domains to trigger T cell activation. The advent of second-generation CARs, which combine activating and costimulatory signaling domains, has led to encouraging results in patients with chemorefractory B cell malignancies (3–7). The translation of this clinical success to solid tumors will require overcoming multiple obstacles, which include achieving sufficient T cell infiltration into tumors and the prevention of tumor immune escape. To overcome the limitations of tumor infiltration and delayed activation observed with systemic T cell administration, we recently demonstrated the merits of regional administration of mesothelin-specific (MSLN-specific) CAR T cells in a clinically relevant model of pleural mesothelioma (8). MSLN is a tumor-associated cell-surface antigen, which we selected on the basis of its overexpression in several cancers and our observations of its association with tumor aggressiveness in mesothelioma and lung and breast cancer patients (9–17). Regional administration of MSLN-targeted CAR T cells establishes long-term systemic immunosurveillance requiring 30-fold lower doses than intravenous administration (8). Aware of potential low T cell infiltration in solid tumors, we investigated CAR T cell efficacy when administered at very low doses.

To eliminate tumor cells, T cells must not only persist, but sustain cytolytic and proliferative function, eluding the inhibitory signals encountered in the tumor microenvironment. The success of second-generation CAR T cells has been attributed to the enhanced T cell persistence afforded by costimulatory signaling domains, such as CD28 and the TNF receptor 4-1BB. However, T cells naturally undergo activation-induced upregulation of coinhibitory pathways, which may limit the antitumor immune response. Programmed death-1 (PD-1), cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), and other coinhibitory receptors are upregulated in T cells following antigen encounter, while tumor cells augment the expression of coinhibitory ligands such as PD-1 ligand (PD-L1) following exposure to T cell–secreted Th1 cytokines (18–20). The success of antibody therapy targeting immune checkpoints such as PD-1 and CTLA-4 underscores the therapeutic potential of counteracting immune inhibition (21–23). However, the success of antibody-mediated checkpoint blockade requires a relatively high mutation burden and the presence of infiltrating T cells (24–26). Adoptive transfer of tumor-targeted T cells may thus fill the void in patients with less immunogenic or “noninflamed” tumors. As adoptively transferred T cells are themselves susceptible to immunoinhibition, strategies that combine adoptive T cell therapy with checkpoint antibody blockade have been investigated using mouse T cells (27–29). Antibody-mediated checkpoint blockade effectively provides reversal of immunoinhibition in a systemic fashion that may result in auto-

Related Commentary: p. 2795

Authorship note: L. Cherkassky and A. Morello contributed equally to this work.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: June 3, 2015; Accepted: May 19, 2016.
immune responses. In contrast, T cell engineering allows one to transduce receptors that selectively counteract tumor-mediated inhibition in targeted T cells.

In this report, we establish that human CAR T cells are subject to inhibition of their cytolytic and cytokine secretion functions upon repeated antigen encounter in vivo. We document the differing abilities of different costimulatory strategies (4-1BB vs. CD28) to withstand repeated antigen stimulation–induced exhaustion and analyzed one of the mechanisms of tolerance (i.e., PD-1 receptor/PD-L1 engagement). We demonstrate that PD-1–mediated CAR T cell exhaustion can be reversed by PD-1 antibody checkpoint blockade. We further describe a PD-1 dominant negative receptor (DNR) that, when cotransduced with a second-generation CAR, mediates enhanced T cell functional persistence.

Figure 1. CARs with CD28 or 4-1BB costimulation exhibit similar cytolytic functions, effector cytokine secretion, and proliferation in vitro upon initial antigen stimulation. (A) First- and second-generation CARs. (B) MSLN–targeted CARs contain the CD3ζ endodomain either alone (Mz, first-generation CAR) or in combination with the CD28 (M28z) or 4-1BB (MBBz) costimulatory domain (second-generation CAR). PSMA–directed CARs with CD28 costimulation (P28z) as well as PSMA–expressing targets (PSMA+) are included in experiments as negative controls. CYT, cytoplasmic domain; LS, leader sequence; LTR, long terminal repeat; SA, splice acceptor; SD, splice donor; TM, transmembrane. (C–E) Antigen-specific effector functions of CAR–transduced T cells. (C) Lysis of MSLN–expressing targets (MSLN+), but not PSMA+ targets, as measured by chromium-release assays. (D) 4-1BB and CD28 costimulations enhance cytokine secretion, as assessed by Luminex assay, after coculture of CAR T cells with MSLN+ cells. (E) M28z and MBBz CARs facilitate robust T cell accumulation after stimulation with MSLN+ cells. (F) 4-1BB and CD28 costimulations decrease the rate of apoptosis as assessed by annexin V/7-AAD+ staining every 7 days after coculture with MSLN+ target. (D and E) ***P < 0.001, comparing costimulated CAR T cells (M28z or MBBz) with the first-generation receptor (Mz), by Student’s t test; significance was determined using the Sidak-Bonferroni correction for multiple comparisons. Data are representative of at least 3 independent experiments and represent the mean ± SEM (C and E) of 3 replicates or are plotted as individual points.
lyse MSTO MSLN+ cells, and MSLN-targeted CARs did not lyse EL4 PSMA+ cells — demonstrating that lysis is antigen specific. Validating the functionality of costimulatory signaling (31), M28z and MBBz CAR T cells secreted 2- to 15-fold higher levels of Th1 cytokines (Figure 1D) and achieved 8- to 14-fold greater T cell accumulation upon repeated exposure to MSLN+ cells when compared with Mz in the absence of exogenous IL-2 (Figure 1E). Furthermore, CAR+ T cells expressing costimulatory molecules (M28z and MBBz) exhibited lower rates of cell death compared with Mz and P28z on day 7 and day 14. No significant difference in cell death was observed between M28z and MBBz (Figure 1F). Having established antigen specificity and validated the functionality of costimulatory signaling domains, we proceeded to evaluate the therapeutic potential of MSLN-targeted CAR T cells in mice bearing established pleural tumors.

M28z is more prone to allowing tumor relapse than MBBz. In an orthotopic model of malignant pleural mesothelioma (MPM) previously established by our laboratory (15, 32–34), serial bioluminescence imaging (BLI) with firefly-luciferase–transduced (ffLuc-transduced) MSTO-211H cells was used to confirm the establishment of tumor, to equalize tumor burden across intervention groups before the initiation of T cell therapy, and to measure the response to therapy as well as T cell resistance to tumor-mediated T cell inhibition. Our results demonstrate the benefit of simultaneously providing costimulation and checkpoint blockade to counteract tumor-mediated T cell inhibition in MSLN-expressing solid tumors.

Results

CARs with CD28 or 4-1BB costimulation exhibit equivalent effector cytokine secretion and proliferation in vitro upon initial antigen stimulation. We constructed 3 CARs that incorporated a human MSLN-specific scFv (30) and either CD3ζ, CD28/CD3ζ, or 4-1BB/CD3ζ signaling domains (Mz, M28z, MBBz) (Figure 1, A and B). The P28z CAR, which is specific for prostate-specific membrane antigen (PSMA), served as a negative effector to control for alloreactivity and xenoreactivity. Both CD4+ and CD8+ human peripheral blood T lymphocytes were effectively transduced using the SFG-retroviral vector (50%–70% transduction) (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI83092DS1). MSLN-transduced MSTO-211H (MSLN+) cells and PSMA-transduced EL-4 mouse lymphoma (MSLN) cells served as MSLN-positive and -negative targets. Mz-, M28z-, and MBBz-transduced T cells demonstrated similar MSLN-specific lysis in vitro (Figure 1C). P28z CAR T cells did not lyse MSTO MSLN+ cells, and MSLN-targeted CARs did not lyse EL4 PSMA+ cells — demonstrating that lysis is antigen specific. Validating the functionality of costimulatory signaling (31), M28z and MBBz CAR T cells secreted 2- to 15-fold higher levels of Th1 cytokines (Figure 1D) and achieved 8- to 14-fold greater T cell accumulation upon repeated exposure to MSLN+ cells when compared with Mz in the absence of exogenous IL-2 (Figure 1E). Furthermore, CAR+ T cells expressing costimulatory molecules (M28z and MBBz) exhibited lower rates of cell death compared with Mz and P28z on day 7 and day 14. No significant difference in cell death was observed between M28z and MBBz (Figure 1F). Having established antigen specificity and validated the functionality of costimulatory signaling domains, we proceeded to evaluate the therapeutic potential of MSLN-targeted CAR T cells in mice bearing established pleural tumors.

M28z is more prone to allowing tumor relapse than MBBz. In an orthotopic model of malignant pleural mesothelioma (MPM) previously established by our laboratory (15, 32–34), serial bioluminescence imaging (BLI) with firefly-luciferase–transduced (ffLuc-transduced) MSTO-211H cells was used to confirm the establishment of tumor, to equalize tumor burden across intervention groups before the initiation of T cell therapy, and to measure the response to therapeutics. The survival curve was analyzed using the log-rank test. *P < 0.05; **P < 0.01. All data are representative of multiple experiments performed with multiple donors.
CAR, no costimulatory signaling included) CAR T cells showed an unsustainable response in terms of tumor burden (Figure 2B) and median survival was 29 days longer than that in the P28z-treated controls (median survival, 45 vs. 16 days, P28z represents a xenoreactivity and alloreactivity control targeting the PSMA antigen) (Figure 2C). Mice treated with M28z CAR T cells had a more uniform reduction in tumor burden and survived longer (median survival, 64 days) than mice treated with first-generation CAR T cells; however, all mice treated with M28z CAR T cells eventually died of progressing tumor. We confirmed that tumor outgrowth was not caused by tumor antigen escape (recurring tumors in mice were found to be MSLN+ by flow cytometric and histologic analysis; data not shown). In contrast, intrapleurally administered MBBz CAR T

Figure 3. M28z- and MBBz-treated mice demonstrate similar early and long-term CAR T cell accumulation, and M28z-treated mice with progressing tumors contain persisting CAR T cells. (A) CD28 and 4-1BB costimulation enhance intratumoral CAR T cell accumulation to equal extents. The left panels show the results of tumor BLI after administration of a single dose of 8 × 10^5 CAR T cells. After 6 days, T cells were harvested from the tumor; x’s denote mice whose T cell counts are represented as data points. The right panel shows absolute CAR T cells per gram of tumor tissue. *P < 0.05. Student’s t tests were performed, and statistical significance was determined using the Sidak-Bonferroni correction for multiple comparisons. (B) CD28 and 4-1BB costimulation enhance CAR T cell persistence, as measured in the spleen, to equal extents. Absolute CAR T cells per spleen are shown 74 days after intrapleural administration of CAR T cells (8 × 10^5). The left panels show the results of tumor BLI; x’s denote mice whose T cell counts are represented as data points. *P < 0.05. Student’s t tests were performed, and statistical significance was determined using the Sidak-Bonferroni correction for multiple comparisons. (C) Mice treated with a low dose of M28z T cells (4 × 10^4) display tumor recurrence with persisting CAR T cells in the spleen and tumor. The left panel shows the results of tumor BLI. Spleen and tumor from mice denoted by an x were harvested and used for FACS analysis (middle panel) and T cell quantification (right panel). Data are representative of multiple tested mice of at least 3 independent experiments.

Both M28z and MBBz CAR T cells intrapleurally administered at a single dose of 1 × 10^7 (effector to target [E:T] ratio of 1:3,000, estimated from tumor burden quantification) (33) were able to eradicate established pleural tumors in the majority of mice (Figure 2A). Since our goal in this study was to investigate the effect of tumor-induced immunoinhibition on T cell exhaustion, we administered CAR T cells to mice bearing established pleural tumors at successively lower doses. We hypothesized that at these lower doses, T cells would be especially susceptible to exhaustion, as they must retain function upon repeated antigen encounters in order to eliminate tumor. It is at these lower doses that we began to see tumor relapse, especially within the M28z cohort (Figure 2A). At the lowest dose tested of 4 × 10^4 (E:T, 1:7,500), mice treated with intrapleural Mz (1st generation CAR, no costimulatory signaling included) CAR T cells showed an unsustainable response in terms of tumor burden (Figure 2B) and median survival was 29 days longer than that in the P28z-treated controls (median survival, 45 vs. 16 days, P28z represents a xenoreactivity and alloreactivity control targeting the PSMA antigen) (Figure 2C). Mice treated with M28z CAR T cells had a more uniform reduction in tumor burden and survived longer (median survival, 64 days) than mice treated with first-generation CAR T cells; however, all mice treated with M28z CAR T cells eventually died of progressing tumor. We confirmed that tumor outgrowth was not caused by tumor antigen escape (recurring tumors in mice were found to be MSLN+ by flow cytometric and histologic analysis; data not shown). In contrast, intrapleurally administered MBBz CAR T
MBBz surpasses M28z CAR T cells at low T cell doses. Improvements in CAR T cell efficacy afforded by costimulatory signaling are typically attributed to improvements in CAR T cell proliferation and/or persistence (2). As expected, M28z and MBBz CAR T cells achieved enhanced intratumoral T cell accumulation compared with Mz CAR T cells (9-fold greater for M28z, 12-fold greater for MBBz) (Figure 3A). Surprisingly, despite the differences in efficacy between M28z and MBBz CAR T cells, we observed similar numbers of tumor-infiltrating T cells between the 2 groups (Figure 3A). Furthermore, M28z and MBBz CAR T cells were equally persistent at long-term time points (Figure 3B). Equal accumulation and persistence were observed for both CD4+ and CD8+ T cell subsets (Supplemental Figure 2). Tumor tissue and spleen from M28z-treated mice that initially had a treatment response but then died of progressing tumor con-
tained circulating T cells as well as tumor-infiltrating T cells, including CAR-positive cells (Figure 3C). This finding demonstrates that the mere persistence of T cells that can effectively traffic to the tumor is not sufficient to eliminate tumor and that the T cell functional status within the tumor microenvironment may be the more critical determinant of clinical outcome. We therefore hypothesized that even costimulated T cells may become exhausted within tumor, especially at low T cell doses that correspond to low E:T ratios. Furthermore, MBBz CAR T cells, which were as persistent as M28z CAR T cells, may be better able to resist exhaustion and retain T cell effector function in order to eliminate a large tumor burden.

MSLN CAR T cells become exhausted upon repeated antigen stimulation in vitro and upon tumor rechallenge in vivo. To assess whether there is ongoing immunoinhibition of CAR T cells and to compare the relative abilities of M28z and MBBz CAR T cells to overcome tumor-mediated immunoinhibition, we injected 1 × 10^5 CAR T cells into the pleural cavities of MSTO MSLN+ tumor–bearing mice, confirmed by upregulation of the activation marker CD69; data not shown), and then performed ex vivo stimulation of harvested CD4+ or CD8+ CAR tumor-infiltrating or splenic T cells with MSLN+ targets (schematic shown in Figure 4A). Uninjected in vitro resting T cells (preinfusion cells) were used to establish the baseline level of function (before antigen exposure). Compared
with resting M28z CD8+ CAR T cells, T cells exposed to MSLN antigen in vivo had lower levels of cytolytic function (Figure 4B) (preinfusion cell lysis, 20.5%; tumor-infiltrating T cell lysis, 13.1%; splenic T cell lysis, 8.7%). In contrast, MBBz CAR T cells retained cytolytic function (preinfusion cell lysis, 18.3%; tumor-infiltrating T cell lysis, 37.2%; splenic T cell lysis, 22.2%). Sorted CD4+ CAR T cells demonstrated a similar pattern of results. We also measured cytokine levels upon ex vivo stimulation of tumor-infiltrating and splenic CAR T cells and observed a decrease in Th1 cytokine secretion for CD4+ M28z CAR T cells exposed in vivo to MSLN + antigen. CD4+ MBBz CAR T cells also demonstrated a decrease in Th1 cytokine secretion, although these cells were better able to retain cytokine secretion when compared with M28z CAR T cells (Figure 4C). CD8+ T cell supernatants contained significantly lower levels of cytokines compared with CD4+ T cell supernatants (a finding previously observed in our model; ref. 8). CD8+ T cells also had a decreased ability to secrete cytokines upon in vivo antigen exposure; CD8+ MBBz CAR T cells preferentially retained their ability to secrete IFN-γ. We next assessed mRNA levels of T cells harvested from tumor and spleen on day 3 after administration and found that the in vivo expression levels of GRZB, IL2, and IFNG were mostly greater for CD4+ and CD8+ MBBz CAR T cells than for M28z CAR T cells, with the exception of IL-2 expression in the CD8+ subset (Figure 4D).

**MBBz CAR T cells show delayed exhaustion upon repeated antigen exposure.** Having demonstrated inhibition of both the cytolytic function and effector cytokine secretion in costimulated CAR T cells exposed to antigen in vivo, we reasoned that repeated antigen stimulation may, similarly to that in models of chronic infection, play a role in T cell inhibition and that differing abilities to retain function upon repeated antigen encounter might explain enhanced efficacy of MBBz CAR T cells. We therefore tested Mz, M28z, and MBBz CAR T cells for their ability to withstand repeated antigen encounter in an in vitro model system, wherein cells were assessed for proliferation, cytolytic function, and cytokine secretion upon MSLN+ antigen stimulation every 7 days. M28z and MBBz CAR T cells had similar abilities to expand upon serial MSLN+ stimulation, expanding to levels 8- to 14-fold greater than those of Mz CAR T cells; they lost the ability to expand following the third stimulation (Figure 5A). Whereas lysis was equal among
The Journal of Clinical Investigation

RESEARCH ARTICLE

3137 jci.org   Volume 126   Number 8   August 2016

antigen, hypothesizing that MBBz CAR T cells would demonstrate enhanced function upon tumor rechallenge. Mice with established MSLN+ pleural tumors were administered intrapleural M28z or MBBz CAR T cells (at a dose of 1 × 10⁵, E:T ratio 1:3,000) to eradicate pleural tumor (Figure 5E). Twenty days after the initial T cell injection, tumor rechallenge was performed by injecting MSLN+ tumor cells (1 × 10⁶) into the pleural cavity of survivors; tumor burden was monitored using BLI. Persisting MBBz CAR T cells were better able to control tumor burden (4 of 4 MBBz-treated mice had a BLI signal at baseline levels vs. 2 of 4 M28z-treated mice) (Figure 5E). Furthermore, an independent experiment also demonstrated the ability of MBBz CAR T cells to eradicate MSLN+ tumor in vivo following 3 tumor rechallenges (data not shown).

Tumor-cell PD-L1 inhibits MSLN CAR T cell effector function. (A) 3T3 fibroblasts were transduced to either express MSLN alone (MSLN+, left) or coexpress MSLN in addition to PD-L1 (MSLN+ PD-L1+, right). (B-D) M28z and MBBz CAR T cell effector functions were assessed after stimulation with 3T3 MSLN+ or MSLN+ PD-L1+ targets. PD-L1 inhibits M28z and MBBz CAR T cell accumulation upon repeated antigen stimulation (B), cytolytic function following 2 stimulations with MSLN+ PD-L1+ tumor cells (C), and Th1 effector cytokine secretion upon the first stimulation (D). Data represent the mean ± SEM of 3 replicates or are plotted as individual points and are representative of at least 2 independent experiments.
The Journal of Clinical Investigation

RESEARCH ARTICLE

RESEARCH ARTICLE

3138

jci.org   Volume 126   Number 8   August 2016

upon initial stimulation (data not shown), chromium-release assay performed with 3T3s as targets following 2 stimulations against MSTO MSLN+ tumor cells demonstrated decreased lytic function in both M28z and MBBz CAR T cells (Figure 7C).

PD-1 antibody therapy rescues M28z CAR T cell function. As PD-1-blocking antibodies demonstrated beneficial effects in the treatment of a variety of malignancies including solid tumors, we next analyzed the ability of PD-1–blocking antibody to rescue exhausted CAR T cells in our model. For this purpose, we selected a PD-1–blocking antibody (clone EH12.2H7) that binds PD-1 receptors on M28z T cells (Figure 8A) and can (a) slightly enhance accumulation (Figure 8B); (b) improve cytotoxic activity (Figure 8C); and (c) improve cytokine secretion (Figure 8D). Next, we evaluated the ability of the PD-1–blocking antibody to rescue exhausted M28z CAR T cells in vivo as shown by tumor BLI in a model treating established high tumor burdens with a single low dose of intrapleurally administered M28z CAR T cells. PD-1-blocking antibody (10 mg/kg) was injected intraperitoneally 3 times on days 30, 35, and 40 or continuously injected every 5 days from day 0 to day 85 following T cell injection. n = 6–9 mice per group. *P < 0.05.

Figure 8. PD-1–blocking antibody restores the effector function of exhausted M28z CAR T cells in vitro and in vivo. (A) M28z CAR T cells were stained with the PD-1–blocking antibody used for functional assays. For in vitro experiments (B–D), M28z CAR T cells were stimulated with MSLN+ tumor cells that had been treated with IFN-γ and TNF-α to upregulate PD-1 ligands. M28z CAR T cells treated with PD-1–blocking antibody (10 μg/ml) demonstrated a small enhancement in accumulation (B), an increase in cytolytic function upon the third stimulation (C), and enhanced effector cytokine secretion (D). Student’s t tests were performed for statistical significance. Data represent the mean ± SEM of triplicates and are representative of 2–3 independent experiments. (E) Injection of PD-1–blocking antibody rescues M28z CAR T cells in vivo as shown by tumor BLI in a model treating established high tumor burdens with a single low dose of intrapleurally administered M28z CAR T cells. PD-1-blocking antibody (10 mg/kg) was injected intraperitoneally 3 times on days 30, 35, and 40 or continuously injected every 5 days from day 0 to day 85 following T cell injection. n = 6–9 mice per group. *P < 0.05.

level (Figure 6, A–C). CD4+ T cells expressed higher levels of PD-1 compared with CD8+ T cells (Figure 6, B and C). We also observed that a significant fraction of both M28z and MBBz CAR T cells coexpressed PD-1 and LAG-3 or PD-1 and TIM-3, suggesting that multiple inhibitory pathways could be functioning simultaneously (Supplemental Figure 4). We next assessed tumor-expressed ligands: PD-L1 and PD-L2 (ligands for PD-1), galectin-9 (ligand for TIM-3), and MHC class II (ligand for LAG-3). Only PD-1 ligands were expressed on pleural tumor cells harvested after intrapleural administration of M28z CAR T cells (Figure 6E). As reported elsewhere (18, 19), coculture of tumor cells with IFN-γ and TNF-α (at concentrations similar to those secreted by T cells, as shown in Figures 1 and 5) resulted in a similar level of upregulation of PD-L1 and PD-L2 expression on tumor cells (Figure 6F), reflecting an adaptation of tumor cells to resist immune attack (adaptive immune resistance). The unique presence of expression of both PD-1 receptor and ligand in vivo suggests that this pathway may play a significant inhibitory role. As some studies have suggested that costimulation may be sufficient to overcome inhibition by PD-1 (35–37), we next assessed whether overexpressed PD-L1 can inhibit CAR T cell function in an in vitro model of PD-L1–mediated immunity. Using 3T3 mouse fibroblasts transduced with either MSLN alone [MSLN+] or both MSLN and PD-L1 [MSLN+PD-L1+] (Figure 7A). In both M28z and MBBz CAR T cells, PD-L1 overexpression resulted in decreased accumulation upon successive stimulation (Figure 7B) and Th1 effector cytokine secretion (Figure 7D). Although tumor-cell lysis was not inhibited upon initial stimulation (data not shown), chromium-release assay performed with 3T3s as targets following 2 stimulations against MSTO MSLN+ tumor cells demonstrated decreased lytic function in both M28z and MBBz CAR T cells (Figure 7C).
have indeed observed in the same experiment that a second cycle of treatment restores the antitumor efficacy of CAR T cells (data not shown), thereby suggesting the necessity of multiple cycles of PD-1 antibody treatment for sustained efficacy. As shown in Figure 8E, multiple, long-term injections of the PD-1 antibody are able to control tumor burden but unable to eradicate the tumor.

**Cell-intrinsic PD-1 resistance rescues M28z CAR T cell function in vivo.** Since our goal was to provide CAR T cell–specific checkpoint blockade that was not reliant on repeated dosing of systemically administered antibodies, we focused on genetically engineered methods of overcoming immunoinhibition. We first constructed a PD-1 DNR that contained the extracellular ligand-binding domain of the receptor fused to a CD8 transmembrane domain. Since the PD-1 DNR lacks any signaling domain, we hypothesized that sufficiently overexpressed receptor would enhance T cell efficacy by saturating PD-1 ligands and thereby blocking signaling through the endogenous PD-1 receptor. We cotransduced M28z CAR T cells with either the PD-1 DNR linked by a P2A element to an mCherry reporter (PD-1 DNR) or an empty vector containing only the reporter (EV) (Figure 9A). M28z CAR T cells cotransduced with either EV (SFG-mCherry) or PD-1 DNR (SFG-2A-PD-1 DNR), CAR T cells sorted for mCherry expression were then incubated for 24 hours with MSLN+ tumor cells that had been treated with IFN-γ and TNF-α to upregulate PD-1 ligands. M28z PD-1 DNR CAR T cells demonstrated a small but statistically significant enhancement in accumulation (B), an enhanced cytolytic function, as measured by chromium-release assay upon the third stimulation with MSLN- PD-L1+ tumor cells (C), and an increased expression of Th1 cytokine secretion (D). Student’s t tests were performed, and statistical significance was determined using the Sidak-Bonferroni correction for multiple comparisons. *P < 0.05; **P < 0.01; ***P < 0.001. Data represent the mean ± SEM of triplicates and are representative of at least 3 independent experiments. (E) Tumor BLI (left) and Kaplan-Meier survival analysis (right) comparing the in vivo efficacy of a single dose of 5 × 10^4 M28z EV (n = 19; grey) or M28z PD-1 DNR (n = 16; blue) pleurally administered. Data shown are a combination of 2 independent experiments. Daggers indicate deaths. Median survival is shown in days following T cell administration. The survival curve was analyzed using the log-rank test (P = 0.001). The log-rank test for each independent experiment was significant at the P < 0.05 level; 2 experiments are combined for illustration.
overcoming PD-1–mediated immunoinhibition, we cotransduced M28z CAR T cells with vectors expressing PD-1-targeting shRNAs (Supplemental Figure 5A), which generated more than 60% PD-1 receptor knockdown at the protein level (Supplemental Figure 5B). In M28z CAR T cells, cotransduction with PD-1 shRNAs enhanced proliferative function upon MSLN+ antigen stimulation (Supplemental Figure 5C), augmented cytotoxicity (Supplemental Figure 5D), and enhanced cytokine secretion upon stimulation with either mesothelioma cells or MSLN+PDL1+ 3T3 mouse fibroblasts (Supplemental Figure 5E) compared with cotransduction with an shRNA targeting a nonmammalian gene (M28z KanR). M28z PD-1 shRNA-transduced T cells did not achieve greater in vivo tumor rejection than M28z KanR T cells, but it is noteworthy that the level of knockdown was notably lower in vivo than in vitro. Thus, use of the PD1 DNR proved to be the more dependable strategy.

Discussion

We demonstrate here that CAR T cell therapy and PD-1 checkpoint blockade are a rational combination in a solid tumor model. To directly counteract PD-1–mediated inhibition, we used retroviral vectors to combine CAR-mediated costimulation with a PD-1 DNR. This combinatorial strategy (costimulation and checkpoint blockade) enhanced T cell function in the presence of tumor PD-L1 expression, resulting in long-term tumor-free survival following infusion of a single low dose of CAR T cells. Our study is relevant to the clinical practice of adoptive T cell therapy and immediately translational for the following reasons: (a) the costimulatory signaling domains tested — CD28 and 4-1BB — are the 2 costimulatory domains used in ongoing clinical trials (ClinicalTrials.gov NCT02414269, NCT02159716, NCT01583686); (b) our models of pleural mesothelioma recapitulate human disease and use large, clinically relevant tumor burdens that elucidate the relevance of T cell exhaustion (8, 15, 32, 33); and (c) our strategy of potentiating CAR T cells by genetically encoded checkpoint blockade uses human sequences that can be readily applied in the clinic (8, 30).

Our study demonstrates that human CAR T cells expressing second-generation CARs can be inhibited upon in vivo antigen exposure within the tumor microenvironment. Earlier studies have reported that agonistic costimulation alone can overcome some solid tumor–expressed inhibitory signaling, which may in part result from the use of immunosensitive in vivo models and the administration of high T cell doses that do not recapitulate the E:T ratios attained in patients with high tumor burdens (35–37). In the present experiments, high CAR T cell doses resulted in tumor eradication regardless of a CD28 or 4-1BB costimulatory domain. It is at the lower T cell doses (and resulting lower E:T ratios) that the effect of exhaustion became apparent. Our findings illustrate the importance of using clinically relevant in vivo models and evaluating the impact of T cell doses. The intraperitoneal T cell doses we used here (4 x 10^4 to 1 x 10^5 per mouse, equivalent to 1.2 x 10^4 to 3 x 10^5/kg) were markedly lower than those used in other mesothelioma xenografts studies (41, 42) and are comparable to doses used in current clinical trials for hematologic malignancies (3, 6) and solid tumors (43, 44). Our experimental design is thus particularly suited to characterizing the role of exhaustion in CAR T cell therapy.

Although both 4-1BB and CD28 costimulatory signaling enhanced T cell persistence to a similar degree, at lower E:T ratios, only treatment with 4-1BB–costimulated T cells eradicated tumors. 4-1BB–costimulated T cells, while still sensitive to tumor-mediated inhibition, were relatively resistant to decline in T cell cytolytic function and cytokine secretion both following in vivo antigen exposure and upon repeated antigen stimulation in vitro. The relative resistance of 4-1BB signaling to immunoinhibition is associated with a PD-1+TBEThi, eomesodermin hi phenotype (45–49), which has been linked to less exhaustion and a more robust cytotoxic effector response in other tumor models and a model of chronic viral infection. This suggests that the criteria for selecting a particular costimulatory signaling strategy among the options available (i.e., 4-1BB, CD28, OX40L, 4-1BBL, CD27, etc.) should extend beyond T cell persistence to functional persistence. The selection of optimal costimulatory pathways will depend on the unique patterns of costimulatory and coinhibitory ligand expression by the tumor, the antigen expression level or density, the affinity of scFv for the tumor antigen, the distance of the tumor epitope from the membrane, and other variations in construct design (such as spacer and transmembrane domains) (2, 50–54). These variables — and not qualitative differences in signaling — may ultimately explain the variability seen in preclinical trials, which alternately conclude that 4-1BB or CD28 is superior, depending on the target antigen and tumor context.

The relatively higher expression of PD-1 in M28z CAR T cells led us to focus on CD28-stimulated CAR T cells. On the basis of this analysis, we pursued genetic strategies for counteracting PD-1 inhibitory signaling, such as generating a PD-1 DNR and shRNAs targeting PD-1. When expressed at sufficient levels, the PD-1 DNR competes with the endogenous PD-1 receptor for binding PD-1 ligands (PD-L1 and PD-L2). CD28–costimulated T cells cotransduced with PD-1 DNR demonstrated enhanced in vitro T cell functions and in vivo T cell efficacy, suggesting that PD-1 signaling is a significant mechanism by which tumor cells evade CAR T cells in our tumor model. Our findings point to the therapeutic promise of adoptively transfected T cells that are genetically engineered to resist tumor-mediated immune inhibition. A DNR that targets TGF-β has been validated in preclinical models and is currently being tested in clinical trials (55, 56).

Enhanced M28z efficacy was also demonstrated with coadministration of PD-1-targeting antibodies, further supporting PD-1 signaling as a significant mechanism of exhaustion in our model and posing an alternative therapeutic strategy for enhancing CAR T cell therapy. However, an obstacle that we observed in these preclinical studies and experienced in the clinic was the requirement for repeated antibody administration for optimal effect. This is in contrast to single administration of M28z PD-1 DNR required for enhanced efficacy. Since multiple parameters (i.e., antibody affinity and regimen, dose and pharmacokinetics, and tumor microenvironment) may influence the efficacy of the PD-1 antibody and PD-1 DNR, these experiments should not be used to infer or determine the superior efficacy of either strategy and, instead, should serve as further evidence of the importance of the PD-1 inhibitory pathway on CAR T cell exhaustion. While one may prefer the genetically engineered strategy for its efficacy, simplicity, and possible decreased risk profile, ultimately, both strat-
egies may be clinically used in concert — PD-1 antibodies used to disinhibit endogenous tumor-reactive T cells and the PD-1 DNR strategy used to boost adoptively transferred CAR T cell response. Our proposed genetic strategy for coinhibitory blockade may overcome another obstacle limiting antibody therapy, the incidence of immune-related adverse events. Because it provides blockade of inhibitory pathways that is limited to a tumor-targeted T cell repertoire, adoptive transfer of PD-1-insensitive T cells may limit the autoimmunity that results from a more broadly applied antibody checkpoint blockade. Nonetheless, additional safety strategies are necessary to limit or prevent potential augmented autoimmunity of the genetically modified PD-1-insensitive T cells. Suicide gene “safety switch” systems already in use in clinical trials, such as iCaspase-9 (57), EGFR mutation (58), and herpes simplex virus thymidine kinase (59), which mediate T cell elimination after administration of a produg or antibody, can be used in PD-1 DNR CAR T cells. We, in fact, have incorporated the iCaspase-9 safety switch within the CAR in our ongoing phase I clinical trial of intrapleural administration of MSLN-targeted CAR T cells (ClinicalTrials.gov NCT02414269).

Our study is unique when compared with other reports characterizing CAR T cell exhaustion. Moon et al. characterize T cell hypofunction within an immunoresistant mesothelioma tumor (20); however, their characterization of inhibition rests on ex vivo experiments. In contrast, we confirm the presence of PD-1-mediated inhibition in vivo and demonstrate gene-engineered checkpoint blockade that can be employed in the clinic. Long et al. recently described CAR T cell exhaustion in a model of osteosarcoma (60) in that they describe an antigen-independent phenomenon that results from tonic signaling of aggregated CAR receptors. The T cells in their model became exhausted during ex vivo expansion, even prior to T cell transfer. Our results characterize a model of T cell exhaustion more akin to that developed in the chronic viral infection literature (61, 62) in which CAR T cell exhaustion is antigen dependent and results from exposure to repeated antigen encounters in an environment rich with inhibitory signaling.

Although we have identified one of the inhibitory mechanisms responsible for CAR T cell exhaustion and highlighted differences in the ability of costimulatory strategies to withstand immunoinhibition, we did not perform an exhaustive assessment of all inhibitory pathways potentially limiting T cell function. That a proportion of mice treated with M28z CAR T cells and PD-1 DNR or PD-1 antibody died of tumor progression suggests the action of other inhibitory mechanisms that remain to be explored. Similarly, that PD-1L expression inhibits MBBz and M28z in vitro but does not inhibit MBBz efficiently in vivo may suggest that PD-1L sensitivity is not the main only factor distinguishing activities of MBBz and M28z CARs. Indeed, we observed that MBBz CAR T cells are associated with a more potent phenotype (TBET$, cedesmomin$, FOXP3$) and also expressed less immunosuppressive cytokines, such as IL-10 and TGF-β, compared with M28z (data not shown).

The literature on chronic infection suggests the existence of other mechanisms of inhibition, both cell intrinsic and cell extrinsic, which have only started to be addressed in tumor-targeted T cell therapies (20, 63). Thus, resistance of MBBz to exhaustion in vivo is possibly a multifactorial resistance to multiple inhibitory mechanisms. Finally, a more complete analysis of the role played by inhibitory signaling would use an immunocompetent model that includes elements such as myeloid-derived suppressor cells and endogenous T cells that have been shown to play important roles in tumor immune evasion.

On the basis of the data presented herein, we have established the importance of tumor-mediated inhibition of human CAR T cell effector functions. By performing a comprehensive analysis of T cell effector functions, we established that costimulated CAR T cells that exhibit enhanced persistence are subject to inhibition upon repeated antigen encounter, both in vitro and within the tumor microenvironment. We have demonstrated the promise of CAR T cell therapy to counteract inhibitory signaling, as it offers the flexibility to engineer signaling domains that provide optimal costimulation and directly counteract inhibitory signals such as PD-1. In our ongoing clinical trial, we are evaluating the upregulation of inhibitory molecules on both the tumor and T cells within the tumor microenvironment. The knowledge acquired from this analysis in combination with the proof-of-principle preclinical experiments presented herein will be highly valuable in improving the efficacy of CAR T cell therapy for solid tumors. As with other solid malignancies, it may be that greater clinical benefit will be achieved by combined checkpoint blockade of multiple inhibitory pathways (e.g., PD-1, CTLA-4, LAG-3) (64). Ultimately, an ideal combination of costimulation with concurrent or adjuvant coinhibitory blockade will maximize CAR T cell potency; the chosen costimulatory and coinhibitory pathways may be tailored to the specific characteristics of tumor and patient.

Methods

General purpose. The purpose of this study was to characterize the mechanisms of tumor-mediated T cell inhibition and to enhance the efficacy of T cell immunotherapy for solid malignancies. We designed MSLN-targeted CARs that, when transduced into human T cells, provide tumor antigen recognition and antigen-specific effector function activation; we also designed signaling domains that provide costimulatory signaling and/or coinhibitory blockade. In vitro, we analyzed cytotoxicity, cytokine secretion, and T cell proliferation. In vivo experiments analyzed strategies for optimizing T cell therapy by use of a clinically relevant mouse model of orthotopic MPM. We used human cancer cells and human T cells to validate and facilitate the translation of our M28z CAR to the clinic, as we have previously demonstrated for CD19 (65) and PSMA (66) CAR T cells. Each experiment was performed multiple times using different donor T cells. To avoid confounding variables — such as differences due to transduction efficiencies and donor-related variability — we present data using a representative experiment, with sample replicates of more than 3.

Cell lines. MSTO-211H human pleural mesothelioma cells (ATCC) were retrovirally transduced to express GFP and fluc fusion protein (MSTO GFP-fluc). These cells were then transduced with the human MSLN variant 1 subcloned into an SFG retroviral vector to generate MSTO MSLN$ GFP-fluc$. Similarly, 3T3 murine fibroblasts (ATCC) were transduced with human MSLN variant 1 alone or with PD-L1 (OriGene cDNA subcloned into SFG vector) to generate 3T3 MSLN$ and 3T3 MSLN$PD-L1$ cells.

γ-Retroviral vector construction and viral production. To generate MSLN-specific CARs, we engineered a cDNA encoding for a fully human scFv m912 specific for MSLN (provided by D. Dimitrov) (30)
linked to the CD8/CD3ζ, CD28/CD3ζ, or CD8/4-1BB/CD3ζ domain, as previously described (67). The control PSMA-specific CAR was generated similarly (66). For construction of the PD-1 DNR, we used commercial gene synthesis to encode the extracellular portion of the PD-1 receptor fused to the CD8 transmembrane and hinge domains. The CAR sequence was inserted into the SFG γ-retroviral vector (provided by I. Riviere, Memorial Sloan Kettering Cancer Center) and linked to a P2A sequence to induce coexpression of the LNGFR reporter (truncated low-affinity nerve growth factor receptor) or, in the case of the PD-1 DNR, the mCherry fluorescent protein reporter (68, 69). The CAR- and PD-1 DNR-encoding plasmids were then transfected into 293T H29 and 293VecRD114 packaging cell lines to produce the retrovirus, as previously described (70).

**T cell isolation, gene transfer, and CD4/CD8 isolation.** Peripheral blood mononuclear cells (PBMCs) were isolated by low-density centrifugation on Lymphoprep (STEM Cell Technology) and activated with phytohemagglutinin (2 μg/ml; Remel). Two days after activation, PBMCs were transduced with 293VecRD114-produced retroviral particles encoding for CARs and PD-1 DNR and spinoculated for 1 hour at 1,800 g on plates coated with retroconectin (15 μg/ml; r-Fibronectin, Takara). Transduced PBMCs were maintained in IL-2 (20 UI/ml; Novartis). Transduction efficiencies were determined by flow cytometric analysis. Pure populations of CD4+ and CD8+ CAR+ T cells or mCherry-positive PD-1 DNR-expressing and mCherry-positive EV-expressing CAR+ T cells were obtained by flow cytometric–based sorting.

**Flow cytometry.** Human MSLN expression was detected using a phycoerythrin-conjugated anti-human MSLN rat IgG2a (R&D Systems). Expression of costimulation or inhibitory proteins on tumor cells was analyzed using the following antibodies: 4-1BBL (PE, clone 5F4; BioLegend), HMC HLA-DR (PE, clone L203; R&D Systems), PD-L1 (APC, clone MIH1; eBioscience), PD-L2 (APC, clone MIH18; eBioscience), and galectin-9 (APC, clone 9M1-3; BioLegend). T cell phenotype and transduction efficiency were determined with monoclonal antibodies for CD3, CD4, CD8, and LNGFR. Expression of T cell inhibitory receptors was analyzed using PD-1 (APC, eBioJ105; eBioscience or EH12.2H7; Biolegend), TIM-3 (PE, clone 344823; R&D Systems), and LAG-3 (PE, clone 9B7W; BioLegend). Cell staining was analyzed using a BD LSRII flow cytometer and FlowJo analysis software (Tree Star Inc.).

**T cell functional assays.** The cytotoxicity of T cells transduced with a CAR or vector control was determined by standard 51Cr-release assays (71). To perform the luciferase-activity assay, CAR+ T cells and MSTD-211H cells expressing MSLN and fluc were incubated for 18 hours at different E:T ratios. Tumor-cell quantity was determined by BLI using IVIS 100 l:umina II, after the addition of 100 μl of d-luciferyl-3 (15 mg/ml) per well, and was compared with the signal emitted under the same conditions and counted on day 14. To determine the rate of apoptosis for different CAR-transduced cells, T cells were collected at the time of seeding on day 0, day 7, and day 14 and stained for apoptosis markers (annexin V/7-AAD).

**Orthotopic pleural mesothelioma animal model and ex vivo experiments.** To develop the orthotopic mouse model of pleural mesothelioma, female NOD/SCIDγ mice (The Jackson Laboratory) aged 4 to 6 weeks were used. Mice were anesthetized using inhaled isoflurane and oxygen, with bupivacaine administered for analgesia. Direct intrapleural injection of 1 × 10^6 to 1 × 10^7 tumor cells in 200 μl of serum-free medium via a right thoracic incision was performed to establish orthotopic MPM tumors (8, 15, 32). In total, 4 × 10^4 to 1 × 10^5 transduced T cells (in 200 μl of serum-free medium) were adoptively transferred into tumor-bearing mice, into the thoracic cavity by direct intrapleural injection. PD-1–blocking antibody (clone EH12.2H7, Biolegend) was injected intraperitoneally at 10 mg/kg every 5 days. Tumor growth was monitored and quantified in vivo by BLI. BLI data were analyzed using Living Image software (version 2.6); BLI signal was reported as total flux (photons per second), which represents the average of ventral and dorsal flux. To analyze the functional capacity of CAR T cells ex vivo, tumor tissues and mouse spleen were processed and analyzed by FACS for phenotyping, or CAR+ or CD8+ T cells were sorted using a FACSaria sorter, then rested for 24 hours in RPMI with IL-2 (60 UI/ml), and 51Cr-release and cytokine-release assays were performed as described above.

**Quantitative real-time PCR.** The mRNA from CD4-LNGFR+ or CD8-LNGFR+ sorted T cells was extracted and reverse transcribed into cDNA using μMACS One-Step cDNA Kit (MACS molecular, Miltenyi Biotech Inc.). Quantitative Real-Time PCR (RT-PCR) was performed with the TaqMan method using Applied Biosystems 7500 systems TaqMan Universal PCR Mastermix and designed by Life Technologies: TBET (Hs00203436_m1); eomesodermin (Hs00172872_m1); granzyme B (Hs01554355_m1); IFN-γ (Hs00174114_m1); and IL-2 (Hs00124636_m1). The comparative Ct of the gene of interest was used and normalized to the β2m housekeeping gene using the following formula: ΔCt(sample) = Ct (gene of interest) – Ct (β2m). The 2^-ΔΔCt method was used to analyze the relative fold change expression compared with the control condition and calculated as follows: 2^-ΔΔCt = 2^-ΔCt(sample) – ΔCt(control).

**Statistics.** Data were analyzed using Prism (version 6.0; GraphPad Software) software and are presented as mean ± SEM, as stated in the figure legends. Results were analyzed using unpaired Student’s t test (2-tailed), with the Sidak-Bonferroni correction used to correct for multiple comparisons when applicable. Survival curves were analyzed using the log-rank test. Statistical significance was defined as P < 0.05. All statistical analyses were performed with Prism software.

**Study approval.** The experimental procedures for the animal studies were approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center.
Author contributions
PSA conceived and designed the study. LC, AM, JVV, and PSA conducted the experiments. PSA, LC, AM, and MS analyzed and interpreted the data. YF and DSD provided the scFv. PSA, LC, AM, MS, and DRJ wrote the manuscript. AM, PSA, LC, JVV, YF, DSD, DRJ, and MS reviewed and revised the manuscript. PSA, MS, and DRJ provided administrative, technical, or material support. PSA supervised the study.

Acknowledgments
The authors’ laboratory work was supported in part by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), grants from the NIH (P30 CA08748 and P50 CA086438-13), the US Department of Defense (PR101053, LC110202, and BC132124), Mr. William H. Goodwin and Alice Goodwin, the Commonwealth Foundation for Cancer Research, the Experimental Therapeutics Center, a Stand Up To Cancer—Cancer Research Institute Cancer Immunology Translational Cancer research grant (SU2C-AACR-DT1012), the DallePézze Foundation, the Derfner Foundation, the American College of Surgeons resident research scholarship, and the ETC Edythe Griffinger Fellowship Program. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. We thank David Sewell and Alex Torres of the Memorial Sloan Kettering Cancer Center (MSK) Thoracic Surgery Service for their editorial assistance. We also thank Nina Lampen and Laurent Schmitt for the electron microscopy image.

Address correspondence to: Prasad S. Adusumilli, Center for Cell Engineering, Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA. Phone: 212.639.8093; E-mail: adusumip@mskcc.org.


62. Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA. 2009;106(2):8623-8628.


